Firas El Chaer, MD

Learn how clinicians personalize polycythemia vera therapy, weighing ruxolitinib vs interferon benefits, side effects, monitoring, and infection risk reduction.

Learn how clinicians choose ruxolitinib vs interferon in polycythemia vera, balancing clot risk, symptom control, and safety monitoring.

Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.

Explore how polycythemia vera symptoms like fatigue and aquagenic pruritus signal disease activity, guiding better monitoring and treatment beyond blood counts.

Experts unpack evolving PV risk signals, from leukocytosis to symptom burden, and when to escalate beyond aspirin, phlebotomy, and hydroxyurea.

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.